Press Releases
Stay up to date with press releases covering announcements, company news, product launches, and business updates.
Publish your press release
Zealand Pharma to participate in the Morgan Stanley 24th Annual Global Healthcare Conference
GlobeNewswire, Inc.
Press release – No. 15 / 2026 Zealand Pharma to participate in the Morgan Stanley 24th Annual Global Healthcare Conference Copenhagen, Denmark, September 9, 2026 - Zealand Pharma A/S (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology company...
CaMaRa Launches with Broad Institute Collaboration to Develop Novel Cardiometabolic and Renal Medicines
GlobeNewswire, Inc.
Company aims to link genetic variants to their biological functions and effects on disease Founding team includes disease genomics expert and Broad Institute Member Melina Claussnitzer, PHD CaMaRa’s business model builds on its founders’ proven...
Ready, Set, Carb: Copenhagen fuels world championship runners with large pasta portions
GlobeNewswire, Inc.
Copenhagen, Denmark, Sept. 09, 2026 (GLOBE NEWSWIRE) -- The last meal before a big race can be make-or-break for runners.
Ascendis Pharma to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference
GlobeNewswire, Inc.
COPENHAGEN, Denmark, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that company executives will participate in a fireside chat at the Morgan Stanley 24th Annual Global Healthcare Conference on Tuesday,...
Zealand Pharma - Transactions related to share buy-back program (week 36, 2026)
GlobeNewswire, Inc.
Company announcement No. 46 / 2026 Zealand Pharma - Transactions related to share buy-back program (week 36, 2026) Copenhagen, Denmark, September 7, 2026 – Zealand Pharma A/S ("the Company" or “Zealand Pharma”) (Nasdaq: ZEAL) (CVR-no. 20045078), a...
Ascendis to Share Its Latest Endocrinology Rare Disease Data at ESPE 2026
GlobeNewswire, Inc.
COPENHAGEN, Denmark, Sept. 07, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced it will share the latest data from its Endocrinology Rare Disease programs during ESPE 2026, the annual congress of the European Society for...
First Infant Data from Ascendis Trial of Once-Weekly TransCon CNP (Navepegritide) Presented at ESPE 2026
GlobeNewswire, Inc.
– Achondroplasia Foramen Magnum Score was stable or improved between baseline and Week 52 with TransCon CNP treatment – Treatment with TransCon CNP increased linear growth in the sentinel cohort, with an improvement in ACH-specific supine length...
New Copenhagen facility to strengthen Europe's quantum manufacturing capabilities
GlobeNewswire, Inc.
COPENHAGEN, Denmark, Sept. 04, 2026 (GLOBE NEWSWIRE) -- The state-of-the-art quantum facility will strengthen Europe’s ability to design, manufacture and scale next-generation quantum chips, helping to position the continent as a global leader in...
Syncromune® Presents SYNC-T™ Therapy: Image-Guided Cryolysis and Intratumoral Immunotherapy at CIRSE 2026
GlobeNewswire, Inc.
FORT LAUDERDALE, Fla. and WEST DES MOINES, Iowa, Sept. 09, 2026 (GLOBE NEWSWIRE) -- Syncromune®, Inc., a privately held clinical-stage biopharmaceutical company developing SYNC-T™, an investigational in situ multi-target immunotherapy platform for...
Correction: Zealand Pharma - Transactions related to share buy-back program (week 35, 2026)
GlobeNewswire, Inc.
Company announcement No. 45 / 2026 Correction: Zealand Pharma - Transactions related to share buy-back program (week 35, 2026) Copenhagen, Denmark, September 2, 2026 – Zealand Pharma A/S ("the Company" or “Zealand Pharma”) (Nasdaq: ZEAL) (CVR-no....
Resalis Therapeutics Appoints Diana M. Røpcke as Chief Medical Officer
GlobeNewswire, Inc.
Dr. Røpcke joins Resalis with extensive experience in clinical drug development as well as expertise in obesity and cardiometabolic therapy areas Torino, Italy, September 2, 2026 – Resalis Therapeutics, a biotechnology company pioneering...
Autonomix Medical Announces Acceptance of Two Abstracts for Poster Presentation at CIRSE 2026
GlobeNewswire, Inc.
Abstracts highlight potential of Autonomix’s transvascular technology across pain management and nervous system mapping THE WOODLANDS, TX, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a...
Zealand Pharma - Transactions related to share buy-back program (week 35, 2026)
GlobeNewswire, Inc.
Company announcement No. 44 / 2026 Zealand Pharma - Transactions related to share buy-back program (week 35, 2026) Copenhagen, Denmark, August 31, 2026 – Zealand Pharma A/S ("the Company" or “Zealand Pharma”) (Nasdaq: ZEAL) (CVR-no. 20045078), a...
Alpine Psychiatry Offers Non-Invasive TMS Treatment Options for Adults Living with Depression
EIN Presswire
Alpine Psychiatry provides FDA-cleared TMS therapy through its Devon, PA partner location for adults with treatment-resistant depression.
Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons
GlobeNewswire, Inc.
Company announcement – No. 43 / 2026 Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons Copenhagen, Denmark, August 28, 2026 – Zealand Pharma...
Food as Medicine Market to Reach USD 400.81 Billion by 2031, Growing at a CAGR of 9.5% — MarketsandMarkets™
GlobeNewswire, Inc.
Delray Beach, FL , Aug. 24, 2026 (GLOBE NEWSWIRE) -- MarketsandMarkets™ estimates the global food as medicine Industry to grow from USD 254.15 billion in 2026 to USD 400.81 billion by 2031, registering a CAGR of 9.5% during the forecast period....
Zealand Pharma – Notification of holding of treasury shares
GlobeNewswire, Inc.
Company announcement – No. 42 / 2026 Zealand Pharma – Notification of holding of treasury shares Copenhagen, Denmark, August 24, 2026 – Zealand Pharma A/S ("the Company" or “Zealand Pharma”) (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology...
Zealand Pharma - Transactions related to share buy-back program (week 34, 2026)
GlobeNewswire, Inc.
Company announcement No. 41 / 2026 Zealand Pharma - Transactions related to share buy-back program (week 34, 2026) Copenhagen, Denmark, August 24, 2026 – Zealand Pharma A/S ("the Company" or “Zealand Pharma”) (Nasdaq: ZEAL) (CVR-no. 20045078), a...
A New Framework Establishes 'The Hallmarks of Skeletal Muscle Health'
EIN Presswire
An international consortium of experts outlines a unifying conceptual framework to transform precision diagnostics, therapeutics, and healthy aging strategies TORONTO, CANADA, August 20, 2026 /EINPresswire.com/ -- Today, an international team of...
UNCF Announces Historic $12 Million Gift from The James and Judith K. Dimon Foundation to Strengthen HBCU Endowments and Expand Pathways in Healthcare and Education
GlobeNewswire, Inc.
Washington, DC, Aug. 20, 2026 (GLOBE NEWSWIRE) -- UNCF announced The Dimon Fund to Advance Economic Opportunity, a historic $12 million gift from The James and Judith K. Dimon Foundation to strengthen the long-term sustainability of historically...
Sign up for:
Healthcare Times Denmark
The daily local news briefing you can trust. Every day. Subscribe now.
Check Your Email!
We sent a one-time activation link to: .
Confirm it's you by clicking the email link.
If the email is not in your inbox, check spam or try again.
Welcome back!
is already signed up. Check your inbox for updates.